• Thursday, June 17, 2021 @ 12:00 am

The positive pivotal “VISION-DMD” trial results of vamorolone in DMD signal a new era for Santhera. Vamorolone has the potential to become a foundational treatment for DMD effectively replacing mainstay steroid therapy irrespective of the underlying genetic mutation, targeting peak sales of CHF 550+ mn, which will be transformational.

Key catalysts include:

  1. Fund raise and partnering vamorolone (H2 2021)
  2. Vamorolone “VISION-DMD” 48-week trial results (Q4 2021)
  3. Vamorolone US DMD filing (Q1 2022)

Read full Santhera Valuation Report "Vamoro-alone"

You may also be interested in